Consequently, reversing human T-cell exhaustion is a crucial mechanism through which patients receiving PD-1 and CTLA-4 pathway drugs achieve significant anti-tumor effects (Blackburn et al., 2009; Schietinger and Greenberg, 2014; Said et al., 2010). The gene discussed is CTLA4; the disease is neoplasm.